Kanabo Group PLC Patent Advancement (6633V)
15 Diciembre 2021 - 1:00AM
UK Regulatory
TIDMKNB
RNS Number : 6633V
Kanabo Group PLC
15 December 2021
Kanabo Group Plc
('Kanabo' or 'the Company')
KANABO'S CBD BASED 'SMOKING CESSATION" FORMULA MOVES CLOSER TO
FULL PATENT APPROVAL
Kanabo Group Plc (LSE:KNB), a medical cannabis and R&D
Company that focuses on the distribution of cannabis-derived
products for medical patients and wellness CBD consumers, is
pleased to announce that its unique CBD and nicotine formula has
advanced from Patent Cooperation Treaty (PCT) phase to National
Phase in the US, UK, and EU countries - the last phase before
becoming an internationally approved patent.
Highlights;
-- Kanabo's unique CBD and nicotine formula has advanced from
PCT phase to National Phase - the last phase before becoming an
internationally approved patent.
-- The formula can be used to treat nicotine and tobacco
addiction, with evidence suggesting the programme significantly
reduces physical and psychological nicotine withdrawal effects by
an average of 70 per cent.
-- The formula is targeted at both the traditional smoking and
e-cigarettes markets which are expected to reach GBP50mil over the
coming years.
Avihu Tamir, CEO Kanabo, said, "Our unique patent pending CBD
formulations and controlled and consistent delivery device, the
VapePod, represents an excellent opportunity for governments to
quickly end the reliance on tobacco for millions of citizens
worldwide. Our tests show a dramatic reduction in nicotine
consumption, whether in cigarettes or e-cigarettes, which can only
be good news for health services around the world."
Kanabo's unique, high potency CBD and nicotine and standalone
CBD formulas, delivered by their proprietary cartridges and
VapePod, can be used to treat nicotine and tobacco addiction, with
evidence so far suggesting the programme significantly reduces
physical and psychological nicotine withdrawal effects. The formula
is targeted at both the traditional smoking and e-cigarettes
markets which are expected to reach GBP50mil over the coming
years.
The application covers a unique new formula of specific
naturally derived terpenes to allow the application of a very
consistent and reproducible, high concentration of CBD throughout
the life of the Kanabo cartridge. Initially, CBD is combined with
Nicotine, which is then reduced over several weeks until there is
zero Nicotine presence.
Tests with a handful of volunteers that participated in Kanabo's
trial, have presented an average reduction of 70 per cent in their
cigarette consumption and did not experience physical or
psychological withdrawal effects.
As countries worldwide continue to seek measures to reduce
tobacco smoking and even ban the use of tobacco products*, Kanabo's
new IP offers a novel and effective way to reduce smoking and
potentially complete withdrawal from Nicotine and e-cigarette
addiction.
For further information, please visit http://www.kanabogroup.com
or contact the following:
Kanabo Group Plc
Avihu Tamir, CEO Via Vox Markets
Peterhouse Capital Ltd
Eran Zucker (Financial Adviser) Tel: +44 (0)20 7469 0930
Lucy Williams / Charles Goodfellow Tel: +44 (0)20 7469 0930
(Corporate Broker)
Vox Markets (Investor Relations)
Kat Perez KanaboGroup@voxmarkets.co.uk
About Kanabo Group Plc
Kanabo Group Plc is a medical cannabis and R&D company
currently selling a range of wellness CBD Products across its
Primary Markets and developing a range of and Medical Cannabis
Products. The company's core strategy is to increase revenues from
the sale of its Retail CBD Products in the wellness sector and to
grow the Kanabo brand through its marketing initiatives. Learn more
at https://www.voxmarkets.co.uk/listings/LON/KNB
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFFIFVLSLIL
(END) Dow Jones Newswires
December 15, 2021 02:00 ET (07:00 GMT)
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024